IMR Press / FBL / Volume 2 / Issue 5 / DOI: 10.2741/A224

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Pancreas transplantation: indications, clinical management, and outcomes
Show Less
1 Transplant Fellow, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
2 Professor & Chief, Section of Pancreatic Transplantation, Department of Surgery University of Minnesota, Minneapolis, Minnesota, USA
3 Professor & Chief, Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
Front. Biosci. (Landmark Ed) 1997, 2(5), 34–40; https://doi.org/10.2741/A224
Published: 1 August 1997
Abstract

Although many advances have been made, pancreas transplantation still poses several challenges to the surgeon, internist and patient. With success rates now above 80% and improving yearly, diabetic patients must make a major life-style decision when considering a pancreas transplant. The main concerns are will the benefits of insulin-independence off-set the risks of surgery and immunosuppression. For diabetics near dialysis and considering a kidney transplant, the decision may not be as difficult. However, for those patients who are failing insulin therapy (brittle control) and remain with good renal function, the options are limited. As the success of pancreas transplantation improves, the procedure may become routine at more centers and become accepted by more third-party carriers. However, as with other solid organs, the availability of pancreases is limited and the supply soon to be exhausted. Thus, further advances are required for the prevention and treatment of Type 1 diabetes. Hopefully, the new frontiers of the next century will allow physicians to identify and preventively treat those at risk for the development of diabetes. Thus, the population of patients suffering from the consequences of this dreadful disease will be greatly reduced. With new developments in immunosuppression and islet transplantation, diabetic patients of the future may be offered the option of a procedure with reduced risks, less morbidity, and improved long-term cure rates.

Share
Back to top